{"analyses":[{"ciLowerLimit":"0.82","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.59","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7936","paramType":"Hazard Ratio (HR)","paramValue":"1.14","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"2.5","value":"2.1"},{"groupId":"OG001","lowerLimit":"2.3","upperLimit":"4.1","value":"3.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"description":"Progression-Free Survival (PFS), based on BICR assessment per RECIST 1.1, was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to \\~2 years).","id":"OG000","title":"Pembrolizumab"},{"description":"Participants received capecitabine, eribulin, gemcitabine, or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice, TPC) in accordance with local regulations and guidelines.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"All participants with PD-L1 CPS ≥10 who were included in a treatment group at randomization","reportingStatus":"POSTED","timeFrame":"Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019)","title":"Progression-Free Survival Per RECIST 1.1 in Participants With PD-L1 CPS ≥10","type":"SECONDARY","unitOfMeasure":"Months"}